Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $11.5 million.

  • Medifast's Gains from Investment Securities rose 83441.89% to $11.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.5 million, marking a year-over-year increase of 74935.06%. This contributed to the annual value of $10.5 million for FY2025, which is 74935.06% up from last year.
  • According to the latest figures from Q4 2025, Medifast's Gains from Investment Securities is $11.5 million, which was up 83441.89% from -$606000.0 recorded in Q3 2025.
  • Medifast's Gains from Investment Securities' 5-year high stood at $37.2 million during Q4 2022, with a 5-year trough of -$41.3 million in Q4 2021.
  • Over the past 5 years, Medifast's median Gains from Investment Securities value was $1963.5 (recorded in 2021), while the average stood at $2.2 million.
  • Data for Medifast's Gains from Investment Securities shows a peak YoY increase of 301400.0% (in 2025) and a maximum YoY decrease of 685306.12% (in 2025) over the last 5 years.
  • Medifast's Gains from Investment Securities (Quarter) stood at -$41.3 million in 2021, then surged by 190.09% to $37.2 million in 2022, then dropped by 6.15% to $34.9 million in 2023, then crashed by 104.48% to -$1.6 million in 2024, then skyrocketed by 834.42% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q4 2025, -$606000.0 for Q3 2025, and -$3.3 million during Q2 2025.